ClinicalTrials.gg
CompletedNCT02252172Updated Oct 20, 2025Results posted

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

A Phase 3 interventional study of Daratumumab IV and Lenalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 206 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
737
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
5th of 132
737 · median 50
Started
2015
with 6 others
Phase 3
24 of 132
4 open now
Registered
7th of 132
by date
Lead sponsor
17 of 132
Janssen Research & Development, LLC

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 5th largest by enrollment, is one of 7 that started in 2015, is one of 24 in phase 3, and was the 7th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).

Read the detailed description

This is a Phase 3, randomized (study drug assigned by chance), open-label (participants and researchers are aware about the treatment, participants are receiving), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), parallel-group (each group of participants will be treated at the same time), and multicenter (when more than one hospital or medical school team work on a medical research study) study in participants with newly diagnosed multiple myeloma and who are not candidates for high dose chemotherapy and ASCT. All the eligible participants will be randomly assigned to receive either lenalidomide and dexamethasone (Rd) (Arm A) or daratumumab in combination with lenalidomide and dexamethasone (DRd) (Arm B). Daratumumab (16 milligram per kilogram [mg/kg]) will be administered weekly for first 8 weeks (Cycles 1 to 2) of treatment and then every other week for 16 weeks (Cycles 3 to 6), then every 4 weeks (from Cycle 7 and beyond) until progression of disease or unacceptable toxicity. Lenalidomide will be administered at a dose of 25 mg orally on Days 1 through 21 of each 28-day cycle, and dexamethasone will be administered at a dose of 40 mg once a week for both treatment arms. Participants in both treatment arms will continue lenalidomide and dexamethasone until disease progression or unacceptable toxicity. All participants randomized to Treatment Arm B (DRd) in this study initially received daratumumab IV formulation; however, following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Participants in Arm A who have sponsor-confirmed disease progression may have the option to receive daratumumab provided by the sponsor (in any subsequent line of therapy) in the Follow-up phase. The study consists of 3 phases: Screening Phase (within 21 days prior to the first dose administration on Day 1), Treatment Phase (Day 1 up to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, consent withdrawal, or study end, whichever occurs first). The maximum duration of study will be 7 years after last participant is randomized. Efficacy will primarily be evaluated by PFS. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Daratumumab
  • JNJ-54767414
  • Lenalidomide
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have documented multiple myeloma satisfying the CRAB (calcium elevation, renal insufficiency, anemia and bone abnormalities) criteria, monoclonal plasma cells in the bone marrow greater than or equal to (>=) 10 percent (%) or presence of a proven plasmacytoma and as defined by any of the following: (a) immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein [M-protein] level >=1.0 gram/deciliter [g/dL] or urine M-protein level >=200 milligram[mg]/24 hours[hrs]; or (b) IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level >=0.5 g/dL or urine M-protein level >=200 mg/24 hrs); or (c) light chain multiple myeloma without measurable disease in serum or urine (serum immunoglobulin free light chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio)
  • Participant must have an (ECOG) performance status score of 0, 1, or 2
  • Participants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age >=65 years; or participants less than (\<) 65 years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below 65 years of age is required before randomization
  • Women of must commit to either abstain continuously from sexual intercourse or to use 2 methods of reliable simultaneously as deemed appropriate by the Investigator. Contraception must begin 4 weeks prior to dosing and must continue for 3 months after the last dose of daratumumab
  • Man, who is sexually active with a woman of child-bearing potential must agree to use a latex or synthetic condom, even if he had a successful vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and for 4 weeks after last dose of lenalidomide and 4 months after last dose of daratumumab

Exclusion criteria

Exclusion Criteria:

  • Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (presence of serum M-protein \<3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the M-protein), or smoldering multiple myeloma (asymptomatic multiple myeloma with absence of related organ or tissue impairment end organ damage)
  • Participant has a diagnosis of Waldenström's disease, or other conditions in which IgM M protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
  • Participant has a history of (other than multiple myeloma) within 5 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)
  • Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of before treatment
  • Participant has had radiation therapy within 14 days of randomization
  • Participant has known (COPD) (defined as a [FEV1] \<50% of predicted normal), persistent asthma, or a history of asthma within the last 2 years (controlled intermittent asthma or controlled mild persistent asthma is allowed)
  • Participants with known or suspected COPD must have a FEV1 test during Screening
  • Participant is known to be seropositive for (HIV) or (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti-HBs and anti-HBc, respectively]) or (anti-HCV antibody positive or HCV-ribonucleic acid [RNA] quantitation positive)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
737 participants (actual)

Study arms

  • Active comparator
    Lenalidomide and Dexamethasone (Rd)

    Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.

    Drug: Daratumumab IV · Drug: Lenalidomide · Drug: Dexamethasone

  • Active comparator
    Daratumumab + Lenalidomide + Dexamethasone (DRd)

    Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.

    Drug: Lenalidomide · Drug: Dexamethasone · Drug: Daratumumab SC

Interventions

  • Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).

    Also known as: JNJ-54767414

  • Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.

  • Dexamethasone 40 mg orally or intravenously once in a week.

  • Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.

    Also known as: JNJ-54767414

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as time from date of randomization to either progressive disease (PD) or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD was defined as an increase of 25 percent (%) from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligram \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\]10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to Plasma cell (PC) proliferative disorder.

    Time frame: From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)

Secondary outcomes

  1. Percentage of Participants With Complete Response (CR) or Better

    Percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria was reported. CR was defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. In participants with only measurable disease by serum FLC levels a normal serum FLC ratio was required. sCR was defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescence, 2-4 color flow cytometry (FC).

    Time frame: From randomization (Day -3) up to 6.6 years

  2. Percentage of Participants With Very Good Partial Response (VGPR) or Better

    VGPR or better rate was defined as the percentage of participants who achieved VGPR or better (VGPR, CR or sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.

    Time frame: From randomization (Day -3) up to 6.6 years

  3. Percentage of Participants With Negative Minimal Residual Disease (MRD)

    MRD negativity rate is defined as the percentage of participants who had negative MRD at any time point after the date of randomization and prior to subsequent antimyeloma therapy. MRD was assessed in participants who achieved CR or better.

    Time frame: From randomization (Day -3) up to 6.6 years

  4. Percentage of Participants With Stringent Complete Response (sCR)

    sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by IHC, immunofluorescence or 2- to 4-color FC. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% PCs in bone marrow.

    Time frame: From randomization (Day -3) up to 6.6 years

  5. Overall Response Rate (ORR)

    ORR was the percentage of participants who achieved partial response (PR) or better (PR, VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels was required in place of the M-protein criteria. If present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required. VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.

    Time frame: From randomization (Day -3) up to 6.6 years

  6. Overall Survival (OS)

    OS was measured from the date of randomization to the date of the death. Median OS was estimated by using the Kaplan-Meier method.

    Time frame: From randomization (Day -3) up to 8.7 years

  7. Time to Disease Progression (TTP)

    TTP was defined as the time from the date of randomization to date of first documented evidence of PD or death due to PD, whichever occurred first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

    Time frame: From randomization (Day -3) up to 6.6 years

  8. Time to Response

    Time to first response, time to VGPR or better, time to CR or better and time to best response was reported for this endpoint. Time to response: time from date of randomization to first efficacy evaluation that met criteria for PR/better as their best response (PR, CR, or better) based on IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. Based on computerized algorithm, according to IMWG response criteria, VGPR or better: proportion of participants with a response of VGPR or better (i.e., VGPR, CR or sCR), CR or better: proportion of participants with a response of CR or better (i.e., CR or sCR).

    Time frame: From randomization (Day -3) up to 6.6 years

  9. Duration of Response (DoR)

    DoR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

    Time frame: From randomization (Day -3) up to 6.6 years

  10. Time to Subsequent Anti-myeloma Treatment

    Time to subsequent anti-myeloma treatment was defined as the time from randomization to the start of subsequent anti-myeloma treatment. Kaplan-Meier method was used for the analysis.

    Time frame: From randomization (Day -3) up to 8.7 years

  11. Progression-free Survival on Next Line of Therapy (PFS2)

    PFS2 was defined as the time from randomization to progression on next line of therapy or death, whichever comes first. Disease progression on next line of treatment was based on investigator judgment.

    Time frame: From randomization (Day -3) up to 6.6 years

  12. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score

    EORTC QLQ-C30 was 30 items self-reporting questionnaire, with 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire included 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related QoL. Scores were transformed to 0 to 100 scale, with higher scores represented better GHS and functioning, and more symptoms. Negative change from baseline values showed deterioration in quality of life or functioning and reduction in symptom and positive values indicated improvement and worsening of symptoms.

    Time frame: Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)

  13. Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS)

    EQ-5D-5L was a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale was designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)

  14. Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score

    EQ-5D-5L was standardized, participant-reported questionnaire to assess health-related quality of life. EQ-5D-5L included 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L VAS. EQ-5D-5L descriptive system provided a profile of participant's health state 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflected increasing levels of difficulty. Participants indicated their health state by selecting the most appropriate level in each of the 5D. Responses to the 5D scores were combined and converted into single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of individual (but allows for values less than 0 by United kingdom scoring algorithm). Higher score indicated better health state.

    Time frame: Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)

  15. Sub-group Analysis: Progression-free Survival (PFS)

    PFS for participants with cytogenic high risk was reported. PFS was time from date of randomization to either PD or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD: an increase of 25% from lowest response value in one of following: serum and urine M-component (absolute increase must be \>=0.5 g/dL and \>=200 mg/24h respectively); Only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved FLC levels (absolute \>10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to PC proliferative disorder. High risk was defined as positive for any of del17p, t(14;16) or t(4;14) by (corrected serum calcium \>11.5 mg/dL) Fluorescence In Situ Hybridization (FISH)/Karyotype.

    Time frame: From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 6.6 years).

  16. Sub-group Analysis: Overall Response Rate (ORR)

    ORR for participants with cytogenic high risk was reported. ORR: percentage of participants who achieved PR/better per IMWG criteria. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg/24h. If serum/urine M-protein were not measurable, decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. If present at baseline, \>=50% reduction in size of soft tissue plasmacytomas was required. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum and urine M-protein \<100mg/24h. CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, \<5% PCs in bone marrow; sCR: CR in addition to normal FLC ratio, absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC. High risk: positive for any of del17p, t(14;16) or t(4;14) by FISH/Karyotype.

    Time frame: From randomization (Day -3) up to 6.6 years

07

Results

Posted Jan 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Started369368
Treated365364
Completed00
Not completed369368
Withdrew: Lost to follow-up96
Withdrew: Death218175
Withdrew: Withdrawal by subject2015
Withdrew: Physician decision01
Withdrew: End of data collection122170
Withdrew: Site closure01

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as time from date of randomization to either progressive disease (PD) or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD was defined as an increase of 25 percent (%) from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligram \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\]10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to Plasma cell (PC) proliferative disorder.

Time frame:
From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Progression-free Survival (PFS)31.87 (28.94 to NA)NA (NA to NA)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.56 · 95% CI 0.43 to 0.73
SecondaryPercentage of Participants With Complete Response (CR) or Better

Percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria was reported. CR was defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. In participants with only measurable disease by serum FLC levels a normal serum FLC ratio was required. sCR was defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescence, 2-4 color flow cytometry (FC).

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response (CR) or Better
Percentage of participantsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Percentage of Participants With Complete Response (CR) or Better30.1 (25.4 to 35.0)51.1 (45.9 to 56.3)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.44 · 95% CI 1.80 to 3.30
SecondaryPercentage of Participants With Very Good Partial Response (VGPR) or Better

VGPR or better rate was defined as the percentage of participants who achieved VGPR or better (VGPR, CR or sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Very Good Partial Response (VGPR) or Better
Percentage of participantsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Percentage of Participants With Very Good Partial Response (VGPR) or Better56.9 (51.7 to 62.0)81.5 (77.2 to 85.4)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.4 · 95% CI 2.42 to 4.77
SecondaryPercentage of Participants With Negative Minimal Residual Disease (MRD)

MRD negativity rate is defined as the percentage of participants who had negative MRD at any time point after the date of randomization and prior to subsequent antimyeloma therapy. MRD was assessed in participants who achieved CR or better.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Percentage of participantsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Percentage of Participants With Negative Minimal Residual Disease (MRD)11.1 (8.1 to 14.8)32.1 (27.3 to 37.1)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Fisher Exact · p = <0.0001 · Odds ratio (or): 3.78 · 95% CI 2.55 to 5.59
SecondaryPercentage of Participants With Stringent Complete Response (sCR)

sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by IHC, immunofluorescence or 2- to 4-color FC. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% PCs in bone marrow.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Stringent Complete Response (sCR)
Percentage of participantsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Percentage of Participants With Stringent Complete Response (sCR)15.7 (12.2 to 19.8)35.6 (30.7 to 40.7)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.98 · 95% CI 2.09 to 4.24
SecondaryOverall Response Rate (ORR)

ORR was the percentage of participants who achieved partial response (PR) or better (PR, VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels was required in place of the M-protein criteria. If present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required. VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Overall Response Rate (ORR)81.6 (77.2 to 85.4)92.9 (89.8 to 95.3)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3 · 95% CI 1.85 to 4.86
SecondaryOverall Survival (OS)

OS was measured from the date of randomization to the date of the death. Median OS was estimated by using the Kaplan-Meier method.

Time frame:
From randomization (Day -3) up to 8.7 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Overall Survival (OS)64.07 (55.98 to 70.80)90.25 (80.76 to NA)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.67 · 95% CI 0.55 to 0.82
SecondaryTime to Disease Progression (TTP)

TTP was defined as the time from the date of randomization to date of first documented evidence of PD or death due to PD, whichever occurred first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Median · Months
Time to Disease Progression (TTP)
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Time to Disease Progression (TTP)40.87 (35.81 to 48.79)NA (NA to NA)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.49 · 95% CI 0.39 to 0.62
SecondaryTime to Response

Time to first response, time to VGPR or better, time to CR or better and time to best response was reported for this endpoint. Time to response: time from date of randomization to first efficacy evaluation that met criteria for PR/better as their best response (PR, CR, or better) based on IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. Based on computerized algorithm, according to IMWG response criteria, VGPR or better: proportion of participants with a response of VGPR or better (i.e., VGPR, CR or sCR), CR or better: proportion of participants with a response of CR or better (i.e., CR or sCR).

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Median · Months
Time to Response
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Time to first response1.05 (0.3 to 22.3)1.05 (0.2 to 12.1)
Time to VGPR or better4.70 (0.9 to 43.3)3.01 (0.9 to 60.9)
Time to CR or better13.17 (2.8 to 54.6)10.66 (1.0 to 46.7)
Time to best response6.31 (0.9 to 55.2)9.97 (0.9 to 60.9)
SecondaryDuration of Response (DoR)

DoR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Median · Months
Duration of Response (DoR)
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Duration of Response (DoR)43.7 (36.8 to 52.6)NA (NA to NA)
SecondaryTime to Subsequent Anti-myeloma Treatment

Time to subsequent anti-myeloma treatment was defined as the time from randomization to the start of subsequent anti-myeloma treatment. Kaplan-Meier method was used for the analysis.

Time frame:
From randomization (Day -3) up to 8.7 years
Reported as:
Median · Months
Time to Subsequent Anti-myeloma Treatment
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Time to Subsequent Anti-myeloma Treatment42.4 (33.5 to 50.6)NA (84.1 to NA)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.51 · 95% CI 0.41 to 0.63
SecondaryProgression-free Survival on Next Line of Therapy (PFS2)

PFS2 was defined as the time from randomization to progression on next line of therapy or death, whichever comes first. Disease progression on next line of treatment was based on investigator judgment.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Median · Months
Progression-free Survival on Next Line of Therapy (PFS2)
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Progression-free Survival on Next Line of Therapy (PFS2)48.89 (44.09 to 56.57)73.72 (73.72 to NA)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.61 · 95% CI 0.49 to 0.76
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score

EORTC QLQ-C30 was 30 items self-reporting questionnaire, with 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire included 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related QoL. Scores were transformed to 0 to 100 scale, with higher scores represented better GHS and functioning, and more symptoms. Negative change from baseline values showed deterioration in quality of life or functioning and reduction in symptom and positive values indicated improvement and worsening of symptoms.

Time frame:
Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)
Reported as:
Least squares mean · Score on scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score
Score on scaleLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Cycle 3 Day 11.4 (-0.7 to 3.5)3.8 (1.7 to 5.8)
Cycle 6 Day 14.8 (2.6 to 7)6.3 (4.3 to 8.4)
Cycle 9 Day 15.7 (3.4 to 8)7.5 (5.4 to 9.7)
Cycle 12 Day 14.5 (2.2 to 6.8)7.8 (5.6 to 9.9)
Cycle 18 Day 14.7 (2.2 to 7.2)6.4 (4.1 to 8.6)
Cycle 24 Day 14.7 (2.1 to 7.4)6.3 (4.1 to 8.6)
Cycle 30 Day 14.5 (1.7 to 7.3)5.5 (3.1 to 7.9)
Cycle 36 Day 15 (2 to 8)7.7 (5.3 to 10.1)
Cycle 42 Day 13.8 (0.6 to 7)5.6 (3.1 to 8.1)
Cycle 48 Day 13.4 (-0.1 to 6.9)4.2 (1.6 to 6.7)
Cycle 54 Day 16.1 (2.2 to 9.9)4.8 (2 to 7.5)
Cycle 60 Day 14.9 (0.4 to 9.4)4.1 (1.1 to 7.1)
Cycle 66 Day 17.1 (1.3 to 12.8)7.7 (4.2 to 11.2)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0986 · Least square mean difference: 2.4 · 95% CI -0.4 to 5.2
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.3042 · Least square mean difference: 1.5 · 95% CI -1.4 to 4.4
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.2339 · Least square mean difference: 1.8 · 95% CI -1.2 to 4.9
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0365 · Least square mean difference: 3.3 · 95% CI 0.2 to 6.3
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.3093 (Cycle 24 Day 1) · Least square mean difference: 1.7 · 95% CI -1.6 to 4.9
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.3481 · Least square mean difference: 1.6 · 95% CI -1.8 to 5
  • Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.5825 · Least square mean difference: 1 · 95% CI -2.6 to 4.6
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.1566 · Least square mean difference: 2.7 · 95% CI -1 to 6.4
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.3858 · Least square mean difference: 1.8 · 95% CI -2.2 to 5.7
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Least Square Mean Difference · p = =0.7296 · Least square mean: 0.8 · 95% CI -3.5 to 5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.5793 · Least square mean difference: -1.3 · 95% CI -6 to 3.3
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.7756 · Least square mean difference: -0.8 · 95% CI -6.1 to 4.5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.8458 · Least square mean difference: 0.7 · 95% CI -6 to 7.4
SecondaryChange From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS)

EQ-5D-5L was a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale was designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

Time frame:
Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)
Reported as:
Least squares mean · Score on scale
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS)
Score on scaleLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Cycle 3 Day 12.1 (0.3 to 4)4.2 (2.3 to 6)
Cycle 6 Day 14.8 (2.8 to 6.8)7.6 (5.8 to 9.5)
Cycle 9 Day 17 (5 to 9.1)9.6 (7.7 to 11.5)
Cycle 12 Day 13.6 (1.6 to 5.7)9.4 (7.4 to 11.3)
Cycle 18 Day 15.4 (3.2 to 7.6)7.4 (5.4 to 9.4)
Cycle 24 Day 14.3 (2 to 6.7)7 (5 to 9)
Cycle 30 Day 14.6 (2.1 to 7)6.9 (4.8 to 9.1)
Cycle 36 Day 14.9 (2.3 to 7.5)8.1 (6 to 10.2)
Cycle 42 Day 14.6 (1.8 to 7.3)5.6 (3.4 to 7.8)
Cycle 48 Day 15.5 (2.4 to 8.5)6.7 (4.5 to 9)
Cycle 54 Day 13.4 (0.1 to 6.7)5.8 (3.4 to 8.2)
Cycle 60 Day 15.8 (1.9 to 9.6)5.2 (2.6 to 7.8)
Cycle 66 Day 16.9 (2 to 11.8)5.6 (2.5 to 8.7)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.1176 · Least square mean difference: 2 · 95% CI -0.5 to 4.5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0336 · Least square mean difference: 2.8 · 95% CI 0.2 to 5.4
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0653 · Least square mean difference: 2.6 · 95% CI -0.2 to 5.3
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0000 · Least square mean difference: 5.8 · 95% CI 3 to 8.5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.1805 · Least square mean difference: 2 · 95% CI -0.9 to 4.8
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0783 · Least square mean difference: 2.7 · 95% CI -0.3 to 5.7
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.1422 · Least square mean difference: 2.4 · 95% CI -0.8 to 5.5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Least Square Mean Difference · p = =0.0575 · Least square mean: 3.2 · 95% CI -0.1 to 6.5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.5339 · Least square mean difference: 1.1 · 95% CI -2.4 to 4.5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.5015 · Least square mean difference: 1.3 · 95% CI -2.4 to 5
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.2512 · Least square mean difference: 2.3 · 95% CI -1.7 to 6.3
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.8246 · Least square mean difference: -0.5 · 95% CI -5.1 to 4.1
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.6640 · Least square mean difference: -1.3 · 95% CI -7 to 4.5
SecondaryChange From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score

EQ-5D-5L was standardized, participant-reported questionnaire to assess health-related quality of life. EQ-5D-5L included 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L VAS. EQ-5D-5L descriptive system provided a profile of participant's health state 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflected increasing levels of difficulty. Participants indicated their health state by selecting the most appropriate level in each of the 5D. Responses to the 5D scores were combined and converted into single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of individual (but allows for values less than 0 by United kingdom scoring algorithm). Higher score indicated better health state.

Time frame:
Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)
Reported as:
Least squares mean · Score on scale
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score
Score on scaleLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Cycle 3 Day 10.081 (0.058 to 0.103)0.097 (0.074 to 0.119)
Cycle 6 Day 10.111 (0.087 to 0.135)0.13 (0.107 to 0.152)
Cycle 9 Day 10.113 (0.088 to 0.138)0.124 (0.101 to 0.147)
Cycle 12 Day 10.103 (0.078 to 0.128)0.132 (0.108 to 0.155)
Cycle 18 Day 10.089 (0.062 to 0.116)0.116 (0.092 to 0.14)
Cycle 24 Day 10.088 (0.059 to 0.116)0.121 (0.096 to 0.145)
Cycle 30 Day 10.088 (0.058 to 0.118)0.102 (0.076 to 0.127)
Cycle 36 Day 10.099 (0.067 to 0.131)0.109 (0.083 to 0.135)
Cycle 42 Day 10.062 (0.028 to 0.096)0.113 (0.086 to 0.14)
Cycle 48 Day 10.075 (0.038 to 0.112)0.082 (0.055 to 0.11)
Cycle 54 Day 10.05 (0.01 to 0.091)0.087 (0.058 to 0.116)
Cycle 60 Day 10.068 (0.02 to 0.115)0.079 (0.047 to 0.111)
Cycle 66 Day 10.041 (-0.019 to 0.102)0.111 (0.073 to 0.148)
Statistical analysis
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.3069 · Least square mean difference: 0.016 · 95% CI -0.015 to 0.046
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.2472 · Least square mean difference: 0.019 · 95% CI -0.013 to 0.05
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.4972 · Least square mean difference: 0.011 · 95% CI -0.021 to 0.044
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0841 · Least square mean difference: 0.029 · 95% CI -0.004 to 0.062
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.1296 · Least square mean difference: 0.027 · 95% CI -0.008 to 0.062
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0762 · Least square mean difference: 0.033 · 95% CI -0.003 to 0.07
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.4859 · Least square mean difference: 0.014 · 95% CI -0.025 to 0.052
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.6031 · Least square mean difference: 0.011 · 95% CI -0.029 to 0.051
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0178 · Least square mean difference: 0.051 · 95% CI 0.009 to 0.093
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.7460 · Least square mean difference: 0.007 · 95% CI -0.038 to 0.053
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.1394 · Least square mean difference: 0.037 · 95% CI -0.012 to 0.086
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.6982 · Least square mean difference: 0.011 · 95% CI -0.045 to 0.068
  • Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd) · Mixed Models Analysis · p = =0.0543 · Least square mean difference: 0.069 · 95% CI -0.001 to 0.14
SecondarySub-group Analysis: Progression-free Survival (PFS)

PFS for participants with cytogenic high risk was reported. PFS was time from date of randomization to either PD or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD: an increase of 25% from lowest response value in one of following: serum and urine M-component (absolute increase must be \>=0.5 g/dL and \>=200 mg/24h respectively); Only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved FLC levels (absolute \>10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to PC proliferative disorder. High risk was defined as positive for any of del17p, t(14;16) or t(4;14) by (corrected serum calcium \>11.5 mg/dL) Fluorescence In Situ Hybridization (FISH)/Karyotype.

Time frame:
From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 6.6 years).
Reported as:
Median · Months
Sub-group Analysis: Progression-free Survival (PFS)
MonthsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Sub-group Analysis: Progression-free Survival (PFS)29.6 (15.6 to 34.5)45.3 (18.4 to 61.9)
SecondarySub-group Analysis: Overall Response Rate (ORR)

ORR for participants with cytogenic high risk was reported. ORR: percentage of participants who achieved PR/better per IMWG criteria. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg/24h. If serum/urine M-protein were not measurable, decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. If present at baseline, \>=50% reduction in size of soft tissue plasmacytomas was required. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum and urine M-protein \<100mg/24h. CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, \<5% PCs in bone marrow; sCR: CR in addition to normal FLC ratio, absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC. High risk: positive for any of del17p, t(14;16) or t(4;14) by FISH/Karyotype.

Time frame:
From randomization (Day -3) up to 6.6 years
Reported as:
Number · Percentage of participants
Sub-group Analysis: Overall Response Rate (ORR)
Percentage of participantsLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
Sub-group Analysis: Overall Response Rate (ORR)75.091.7

Adverse events

Collected over All-cause mortality: From randomization (Day -3) up to 8.7 years; Serious and Other AEs: From start of treatment (Day 1) up to 6.6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide + Dexamethasone (Rd)259/369 (70.2%)262/365 (71.8%)358/365 (98.1%)
Daratumumab + Lenalidomide + Dexamethasone (DRd)287/368 (78%)289/364 (79.4%)362/364 (99.5%)
Most frequent serious events
Showing 10 of 492
Most frequent serious events
EventLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
PneumoniaInfections and infestations39/36568/364
PyrexiaGeneral disorders12/36520/364
InfluenzaInfections and infestations8/36517/364
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders14/36516/364
BronchitisInfections and infestations6/36515/364
Atrial FibrillationCardiac disorders15/36510/364
Acute Kidney InjuryRenal and urinary disorders15/36514/364
Back PainMusculoskeletal and connective tissue disorders9/36514/364
Urinary Tract InfectionInfections and infestations7/36512/364
AnaemiaBlood and lymphatic system disorders12/3656/364
Most frequent other events
Showing 10 of 112
Most frequent other events
EventLenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)
DiarrhoeaGastrointestinal disorders186/365237/364
NeutropeniaBlood and lymphatic system disorders167/365224/364
FatigueGeneral disorders114/365163/364
ConstipationGastrointestinal disorders136/365156/364
Oedema PeripheralGeneral disorders117/365156/364
AnaemiaBlood and lymphatic system disorders148/365154/364
Back PainMusculoskeletal and connective tissue disorders107/365147/364
AstheniaGeneral disorders99/365134/364
NauseaGastrointestinal disorders87/365133/364
InsomniaPsychiatric disorders116/365125/364

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)Total
Mean74.2 ± 5.6674.0 ± 5.4474.1 ± 5.55
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)Total
Female174179353
Male195189384
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)Total
Hispanic or Latino121123
Not Hispanic or Latino352347699
Unknown or Not Reported51015
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)Total
White339336675
Black or African American161228
Asian235
American Indian or Alaska Native000
Native Hawaiian or other Pacific Islander101
Other6612
Unknown123
Not Reported4913
Region of Enrollment
Region of Enrollment(Participants)Lenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)Total
Australia181735
Austria11314
Belgium527
Canada282452
Denmark61016
France155157312
Germany161935
Ireland347
Israel358
Italy336
Netherlands145
Sweden121022
United Kingdom343367
United States7477151
Stage of Disease (ISS)
Stage of Disease (ISS)(Participants)Lenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)Total
Stage I10398201
Stage II156163319
Stage III110107217
Time from Multiple Myeloma (MM) diagnosis
Time from Multiple Myeloma (MM) diagnosis(Months)Lenalidomide + Dexamethasone (Rd)Daratumumab + Lenalidomide + Dexamethasone (DRd)Total
Mean1.3 ± 1.41.4 ± 1.51.3 ± 1.5
08

Study locations

206 sites
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Glendale, Arizona, United States
  • Berkeley, California, United States
  • Beverly Hills, California, United States
  • El Cajon, California, United States
  • Greenbrae, California, United States
  • Los Angeles, California, United States
  • Oceanside, California, United States
  • San Diego, California, United States
  • West Hills, California, United States
  • Whittier, California, United States
  • Denver, Colorado, United States
  • Fort Collins, Colorado, United States
  • Glenwood Springs, Colorado, United States
  • New Haven, Connecticut, United States
  • Norwalk, Connecticut, United States
  • Washington D.C., District of Columbia, United States
  • Boca Raton, Florida, United States
  • Boynton Beach, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Fort Myers, Florida, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Lake City, Florida, United States
  • St. Petersburg, Florida, United States
  • Weston, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Macon, Georgia, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Niles, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Iowa City, Iowa, United States
  • Louisville, Kentucky, United States
  • Lafayette, Louisiana, United States
  • Marrero, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Annapolis, Maryland, United States
  • Baltimore, Maryland, United States
  • Frederick, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Duluth, Minnesota, United States
  • Rochester, Minnesota, United States
  • Kansas City, Missouri, United States
  • St Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Hooksett, New Hampshire, United States
  • Brick, New Jersey, United States
  • Hackensack, New Jersey, United States
  • Livingston, New Jersey, United States
  • Plainfield, New Jersey, United States
  • Summit, New Jersey, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Asheboro, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Pinehurst, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Canton, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Bend, Oregon, United States
  • Bethlehem, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Spartanburg, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • Chattanooga, Tennessee, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • Edinburg, Texas, United States
  • Fort Sam Houston, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Plano, Texas, United States
  • San Antonio, Texas, United States
  • Ogden, Utah, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Tacoma, Washington, United States
  • Box Hill, Australia
  • Fitzroy, Australia
  • Footscray, Australia
  • Kogarah, Australia
  • Kurralta Park, Australia
  • Nedlands, Australia
  • New South Wales, Australia
  • Woodville, Australia
  • Woolloongabba, Australia
  • Innsbruck, Austria
  • Linz, Austria
  • Salzburg, Austria
  • Vienna, Austria
  • Wien Wien, Austria
  • Bruges, Belgium
  • Brussels, Belgium
  • Haine Saint Paul La Louviere, Belgium

Showing the first 100 of 206 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bahlis N, Facon T, San-Miguel J, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje N, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel K, Mohty M, Leleu X, Plesner T, Jakubowiak A, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 Jul 14;10(13):4541-4550. doi: 10.1182/bloodadvances.2025019323. PubMed 42085642 ↗
  • Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr;39(4):942-950. doi: 10.1038/s41375-024-02505-2. Epub 2025 Feb 27. PubMed 40016302 ↗
  • Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Wang G, Gupta-Werner N, Kaila S, Pei H, Matt K, Gries KS, Carson R, Borgsten F, Weisel K. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. Eur J Haematol. 2025 May;114(5):883-889. doi: 10.1111/ejh.14392. Epub 2025 Feb 14. PubMed 39952901 ↗
  • Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar;39(3):710-719. doi: 10.1038/s41375-024-02506-1. Epub 2025 Jan 15. PubMed 39815052 ↗
  • Almansour SA, Alqudah MAY, Abuhelwa Z, Al-Shamsi HO, Alhuraiji A, Semreen MH, Bustanji Y, Alzoubi KH, Modi ND, Mckinnon RA, Sorich MJ, Hopkins AM, Abuhelwa AY. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. Ther Adv Med Oncol. 2024 Sep 2;16:17588359241275387. doi: 10.1177/17588359241275387. eCollection 2024. PubMed 39229471 ↗
  • Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, Perrot A, Weisel K, Raje N, Macro M, Frenzel L, Leleu X, Wang J, Rampelbergh RV, Uhlar CM, Vermeulen J, Duran J, Borgsten F, Usmani SZ. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma. Future Oncol. 2023 Apr;19(13):887-895. doi: 10.2217/fon-2023-0082. Epub 2023 May 22. PubMed 37212642 ↗
  • Mateos MV, Rigaudeau S, Basu S, Spicka I, Schots R, Wrobel T, Cook G, Beksac M, Gries KS, Kudva A, Tromp B, Van Rampelbergh R, Pei H, Wroblewski S, Carson R, Delioukina M, White D. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. J Oncol Pharm Pract. 2023 Jul;29(5):1172-1177. doi: 10.1177/10781552221103551. Epub 2022 Sep 6. PubMed 36067063 ↗
  • Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13. PubMed 34655533 ↗
  • Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101. PubMed 34289038 ↗
  • San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 Jan 27;139(4):492-501. doi: 10.1182/blood.2020010439. PubMed 34269818 ↗
  • Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 Jan 20;39(3):227-237. doi: 10.1200/JCO.20.01370. Epub 2020 Dec 16. PubMed 33326255 ↗
  • Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. PubMed 31141632 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Sep 2018, 43 months.

Results were first posted in Jan 2020, 1 year 3 months after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 43 months is close to that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2014
First posted
Sep 30, 2014
StartActual
Feb 16, 2015
Primary completionActual
Sep 24, 2018
CompletionActual
Oct 2, 2024
Results first posted
Jan 9, 2020
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02252172
Responsible party
Sponsor
First posted
Sep 30, 2014
Start date
Feb 16, 2015
Primary completion
Sep 24, 2018
Completion
Oct 2, 2024
Results posted
Jan 9, 2020
Last update
Oct 20, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion